Advertisement

Topics

PubMed Journals Articles About "Latanoprost Xalatan Ocular Hypertension" RSS

23:26 EST 4th December 2016 | BioPortfolio

Latanoprost Xalatan Ocular Hypertension PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Latanoprost Xalatan Ocular Hypertension articles that have been published worldwide.

More Information about "Latanoprost Xalatan Ocular Hypertension" on BioPortfolio

We have published hundreds of Latanoprost Xalatan Ocular Hypertension news stories on BioPortfolio along with dozens of Latanoprost Xalatan Ocular Hypertension Clinical Trials and PubMed Articles about Latanoprost Xalatan Ocular Hypertension for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Latanoprost Xalatan Ocular Hypertension Companies in our database. You can also find out about relevant Latanoprost Xalatan Ocular Hypertension Drugs and Medications on this site too.

Showing "latanoprost Xalatan Ocular Hypertension" PubMed Articles 1–25 of 3,100+

Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study.

To evaluate the safety and efficacy of unpreserved latanoprost eye drops (UNL) in comparison with preserved latanoprost eye drops (LBAK) in patients with glaucoma or ocular hypertension stabilized with preserved latanoprost eye drops as monotherapy.


Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.

This study compared the efficacy, safety, and pharmacokinetics of a preservative-free latanoprost formulation to an established, benzalkonium chloride (BAK)-containing formulation for the treatment of open-angle glaucoma or ocular hypertension.

Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial.

To assess the noninferiority of a dorzolamide-timolol fixed combination (DTFC) versus latanoprost in terms of intraocular pressure (IOP) and to compare blood pressure (BP), ocular perfusion pressure (OPP) and diastolic ocular perfusion pressure (DOPP) between the latanoprost and DTFC groups in patients with normal-tension glaucoma (NTG).


Hypertension and the eye.

Hypertension is the primary risk factor for cardiovascular disease and mortality that consists a major public health issue worldwide. Hypertension triggers a series of pathophysiological ocular modifications affecting significantly the retinal, choroidal, and optic nerve circulations that result in a range of ocular effects.The retina is the only place in the body where microvasculature can be directly inspected, providing valuable information on hypertension related systemic risks.The aim of this review is...

OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.

To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s).

Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa.

Success of the long-term glaucoma therapy and preservation of the visual function strongly depend on patients' compliance which may be affected by the inconvenience of treatment and its side effects. Recently, introduction of preservative-free anti-glaucoma agents has become an important step towards improved glaucoma care by eliminating the negative effects of preservatives on the eye surface. Although, newly developed eye drop formulations do not contain standard preservatives, they still can be harmful t...

Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.

To compare the diurnal intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% every evening (qpm) with timolol maleate 0.5% twice daily (BID) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Factors Influencing the Placebo Effect in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: An Analysis of Two Randomized Clinical Trials.

To explore factors related to the placebo effect in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).

Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma.

To evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and ocular hypertension (OHT) or exfoliative glaucoma (XFG) and examine any lasting effect on intraocular pressure (IOP) after discontinuation.

Assessing Precision of Hodapp-Parrish-Anderson Criteria for Staging Early Glaucomatous Damage in an Ocular Hypertension Cohort: A Retrospective Study.

The aims of the study were (1) to stage early glaucomatous field defects following Hodapp-Parrish-Anderson (HPA) criteria in an ocular hypertension (OH) cohort with 7-year follow-up and (2) to recognize the limitation(s) of this staging system.

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.

PurposeTo determine whether intraocular pressure (IOP) lowering with fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) was superior to that of vehicle+PGA in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis 6-week, multicenter, randomized, double-masked, parallel-group trial was conducted at 30 clinical sites in the United States between October 2013 and May 2014. Eligible patients were adults...

Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.

To assess pharmacodynamic and safety profiles of ONO-9054 following single and multiple day dosing in subjects with ocular hypertension or open-angle glaucoma.

Ocular Hypertension Requiring Suspension of Inhaled Corticosteroids.

The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.

Vogt-Koyanagi-Harada (VKH) syndrome is a systemic inflammatory autoimmune disease with associated ophthalmic pathology. Glaucoma has been reported in patients with VKH. The purpose of this report is to examine the frequency and types of glaucoma associated with VKH.

Bilateral neuroinflammatory processes in visual pathways induced by unilateral ocular hypertension in the rat.

Glaucoma is one of the leading causes of irreversible blindness in the world. The major risk factor is elevated intraocular pressure (IOP) leading to progressive retinal ganglion cell (RGC) death from the optic nerve (ON) to visual pathways in the brain. Glaucoma has been reported to share mechanisms with neurodegenerative disorders. We therefore hypothesize that neuroinflammatory mechanisms in central visual pathways may contribute to the spread of glaucoma disease. The aim of the present study was to anal...

Ocular and Cerebrospinal Fluid Penetration of Antiretroviral Agents.

The ocular penetration of systemically administered antiretroviral drugs (ARVs), which is important in the clinical setting of HIV uveitis, is unknown. This study aimed to assess the ocular penetration of different antiretroviral drugs in an animal model.

Risk Factors for Glaucoma in a Cohort of Patients with Fuchs Heterochromic Iridocyclitis.

To describe the incidence and risk factors for ocular hypertension and/or glaucoma in patients with Fuchs heterochromic iridocyclitis (FHC).

Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.

Intraocular pressure (IOP) is the most significant modifiable risk factor to prevent onset or progression of glaucoma. Glaucoma prevalence continues to increase, emphasizing the need for improved ocular hypotensive treatment options. To try to improve on both tolerance and IOP control of currently available therapies, different receptors or mechanisms are being explored to reduce IOP more effectively and to improve tolerance.

Ocular manifestations of inflammatory bowel disease.

Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are numerous and can often involve the eye. This review highlights the ocular complications associated with IBD including the critical role the ophthalmologist can play in the diagnosis of IBD, the pathogenesis of IBD, its ocular complications, and the treatment of ocular inflammation associated with IBD.

The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension.

Pulmonary hypertension is a progressive disorder which often leads to right ventricular failure and death. While the existing classification system for pulmonary hypertension does not account for the impact of diabetes mellitus, evidence is emerging that suggests that diabetes is associated with pulmonary hypertension and that diabetes modifies the course of pulmonary hypertension. There is also growing radiographic, hemodynamic, biochemical, and pathologic data supporting an association between diabetes an...

Effect of different methods of polymerizing ocular prosthesis acrylic resin on a human conjunctival cell line.

Ocular prosthesis acrylic resins should be biocompatible regardless of the polymerization method. No study has evaluated the biocompatibility of ocular prostheses.

Effect of Morphological and Functional Parameters on Ocular Pulse Amplitudes: An Analysis in Ocular Hypertension and Different Types of Glaucoma.

Background and Purpose: Ocular blood flow imbalance and the loss of autoregulation are widely believed to be important factors in the pathogenesis of glaucoma. The purpose of this study was to investigate the impact of morphometric and functional changes on ocular pulse amplitude (OPA) in normal tension glaucoma (NTG), primary open-angle glaucoma (POAG), pseudoexfoliation-glaucoma (PEX) and ocular hypertension (OHT). Patients and Methods: This prospective study included 172 patients with manifest glaucoma a...

Ocular injuries from fireworks: the 11-year experience of a US level I trauma center.

PurposeCharacterize ocular trauma and visual outcomes from firework injuries at a level I trauma center.MethodsRetrospective review of all firework injuries at Harborview Medical Center between 2003 and 2013.ResultsThree hundred and twenty-seven patients sustained firework injuries, of which 100 (31%) sustained ocular injuries. The average age of all patients who sustained fireworks injuries was 24.2 years, 89% were male and 54% of injuries occurred within 48 h of 4 July. Ocular injuries were most commonl...

Prostanoid Receptor Antagonist Effects on Intraocular Pressure, Supported by Ocular Biodisposition Experiments.

Since all prostanoid receptors affect intraocular pressure (IOP) and endogenous prostanoids are found in ocular tissues, the pressor effects of prostanoid antagonists were comprehensively evaluated. The absence of effects of most of these antagonists was not entirely anticipated. To ensure no false-negative results, ocular biodisposition studies were conducted.

Copeptin is increased in resistant hypertension.

The participation of vasopressin in the mechanisms of resistant hypertension is unclear. We compared plasma copeptin concentration, a surrogate marker for vasopressin secretion, between patients with resistant hypertension and those with controlled blood pressure (CBP), in a post hoc analysis of the Prise en charge de l'Hypertension Artérielle RESistante au traitement trial.


Quick Search
Advertisement